Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment
NCT04091542 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2023-01-04
Summary
With the HOBBIT trial, the investigators want to develop a technology that allows volunteers to hold their breath for a long time. This technique will then be taught to patients with breast cancer to be able to hold their breath long-term during the irradiation. After all, research has shown that the heart is in a better position when the patient enters her breath after a deep inhalation, as a result of which there is less unwanted radiation of the heart. To develop this technique the investigators use healthy volunteers, who are asked several times to hold their breath as long as comfortable. Before the respiratory arrest the investigators allow these volunteers to hyperventilate, administer oxygen and cause hyperinflation of the lungs.
The volunteers come back four times, on four consecutive days. The first day they receive a short training. Afterwards oxygen is administered for a few minutes while the volunteers are asked to hyperventilate. Afterwards, by using the learned technique, they must hold their breath for as long as possible, comfortably. They should hold their breath 3 times in total with a short break in between. The following days there is always a change in the preparation protocol, compared to the previous study. Different parameters in the protocol will be changed for different groups of volunteers, this is based on randomization. In this way the effect of different parameters in the preparation of the AHS can be investigated. The investigators will use this information to develop a new protocol for extending the duration of breathing to two minutes and thirty seconds for use during radiotherapy treatment. The method for finding the optimal technique is iterative optimization. This method follows a process of development, testing, feedback and redevelopment cycles. Iteratively, these cycles of development use the prior research to further elaborate the most promising discoveries and drop paths that do not produce the desired result. During the development The investigators listen to the input of different people: doctors, nurses, support staff, engineers and the participants, to guarantee the usability of the technique on the radiotherapy device. Once the researchers think they have found a solution that meets all the conditions, a group of untrained volunteers are asked to implement the technique. With this the investigators validate the technique for later use in breast cancer patients.
Conditions
Interventions
- DEVICE
-
Optiflow/Ventilator
Participants will have 2 days with optiflow, 2 days with ventilator.
Sponsors & Collaborators
-
University Hospital, Ghent
lead OTHER
Principal Investigators
-
Liv Veldeman, dr · University Ghent
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-03-15
- Primary Completion
- 2019-12-31
- Completion
- 2021-02-22
Countries
- Belgium
Study Locations
More Related Trials
-
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
NCT01917279 ·Status: UNKNOWN ·Phase: PHASE3
-
Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer
NCT05747326 ·Status: UNKNOWN ·Phase: PHASE2
-
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
NCT00146549 ·Status: COMPLETED ·Phase: PHASE3
-
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
NCT00002755 ·Status: COMPLETED ·Phase: PHASE3
-
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
NCT02177175 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
NCT03775525 ·Status: UNKNOWN ·Phase: PHASE1
-
This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.
NCT06973525 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement
NCT00003902 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
NCT06685796 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis
NCT03295916 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
NCT01387295 ·Status: COMPLETED ·Phase: PHASE2
-
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
NCT00031278 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study
NCT06890871 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
NCT03955640 ·Status: TERMINATED ·Phase: PHASE1
-
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
NCT00194727 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
NCT01363986 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
NCT00277069 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
NCT01289353 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer
NCT02527317 ·Status: COMPLETED
-
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
NCT00444587 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
NCT00033514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
NCT02538471 ·Status: TERMINATED ·Phase: PHASE2
-
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
NCT01387373 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
NCT00017394 ·Status: COMPLETED ·Phase: PHASE2